Interestingly, randomized clinical trials (RCTs) showed an increased rate of myocardial infarction (MI) with dabigatran [5,6,7], while the FXa inhibitors rivaroxaban and apixaban reduced the incidence of MI compared to warfarin [4], which warrants further investigations. Here, F10 is linked to myocardial infarction.